Accordingly, a study in a CT26 tumor model showed that a triple blockade of VISTA/PD-1/CTLA-4 could improve the efficacy of PD-1/CTLA-4 dual blockade by promoting antigen-presentation in myeloid cells and reducing the quiescent state of CTLs (107). The gene discussed is CTLA4; the disease is neoplasm.